Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year to $396.7 million. The company’s full-year revenue guidance of $1.58 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $0.85 per share was 17.1% above analysts’ consensus estimates.

Is now the time to buy Phibro Animal Health? Find out in our full research report.

Company Overview

With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ:PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.

Revenue Growth

Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Phibro Animal Health grew its sales at a solid 12.7% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Phibro Animal Health’s annualized revenue growth of 22.1% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.

This quarter, Phibro Animal Health reported modest year-on-year revenue growth of 4.8% but beat Wall Street’s estimates by 6.8%.

Looking ahead, sell-side analysts expect revenue to grow 1% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will see some demand headwinds.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Operating Margin

Operating margin is a key measure of profitability. Think of it as net income – the bottom line – excluding the impact of taxes and interest on debt, which are less connected to business fundamentals.

Phibro Animal Health was profitable over the last five years but held back by its large cost base. Its average operating margin of 8.9% was weak for a healthcare business.

On the plus side, Phibro Animal Health’s operating margin rose by 4.4 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company’s margin has increased by 7.6 percentage points on a two-year basis.

This quarter, Phibro Animal Health generated an operating margin profit margin of 12.2%, up 3.3 percentage points year on year. This increase was a welcome development and shows it was more efficient.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

Phibro Animal Health’s EPS grew at 20.4% compounded annual growth rate over the last five years, higher than its 12.7% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

We can take a deeper look into Phibro Animal Health’s earnings to better understand the drivers of its performance. As we mentioned earlier, Phibro Animal Health’s operating margin expanded by 4.4 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, Phibro Animal Health reported adjusted EPS of $0.85, up from $0.57 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Phibro Animal Health’s full-year EPS to stay about the same, moving from $3.21 to $3.24.

Key Takeaways from Phibro Animal Health’s Q2 Results

We were impressed by how significantly Phibro Animal Health blew past analysts’ revenue expectations this quarter. We were also excited its full-year EPS guidance outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this quarter featured some important positives. The stock traded up 7.3% to $38.78 immediately after reporting.

Phibro Animal Health put up rock-solid earnings, but one quarter doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).